SYNGR3 and breast carcinoma: For example, SYNGR3 was included in a prognostic gene signature as being downregulated in chemotherapy-resistant breast cancer cell lines where addition of a histone deacetylase inhibitor (SAHA) was effective (137), supporting our finding that high SYNGR3 may indicate better prognosis.